ABBVIE Stock- AbbVie requests Supreme Court review of ‘sham’ patent litigation ruling
AbbVie Inc. has asked the U.S. Supreme Court to review a federal appeals court ruling that it and partner Besins Healthcare Inc. violated antitrust law by filing a “sham” patent complaint to delay a generic version of its blockbuster testosterone replacement drug AndroGel.
In a petition for certiorari filed on Thursday, Seth P. Waxman of Wilmer Cutler Pickering Hale & Dorr argued on behalf of the North Chicago, Illinois-based pharmaceutical company that the 3rd U.S. Circuit Court of Appeals wrongly decided that the complaint was a sham without showing it had acted in bad faith. To read the full story on Westlaw Today, click here: bit.ly/38YXHaP